JAZZ Stock Recent News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.

– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav ® and Epidiolex ® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera ® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN , Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion.

DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m.

Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DUBLIN , Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.